Home
Storia in 1 fonti
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal year 2026. | BMS and Hengrui signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal 2026. Daiichi Sankyo aims to be a global top-5 oncology player while expanding beyond antibody-drug conjugates. Plus more.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
Takeda, slimming down for 'new era,' plots 4,500 layoffs in latest restructuring drive
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake off the generic-related declines that have plagued…
- ·
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal year 2026. | BMS and Hengrui signed a massive deal…